First-line treatment in metastatic colorectal cancer: Important or crucial?

被引：5
|
作者：
Malka, David [1 ]
Rotolo, Federico [2 ,3 ]
Boige, Valerie [1 ]
机构：
[1] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France
[2] Univ Paris Saclay, Serv Biostat & Epidemiol, Gustave Roussy, Villejuif, France
[3] Univ Paris Sud, Univ Paris Saclay, UVSQ, CESP,INSERM, Villejuif, France
来源：
EUROPEAN JOURNAL OF CANCER | 2017年 / 84卷
关键词：
PROGRESSION-FREE SURVIVAL; FOLFIRI PLUS CETUXIMAB; KRAS WILD-TYPE; EARLY TUMOR SHRINKAGE; PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; RANDOMIZED PHASE-3; 2ND-LINE TREATMENT; TREATMENT LINES;
D O I：
10.1016/j.ejca.2017.09.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：363 / 366
页数：4
相关论文
共 50 条
  • [21] ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer
    Grancher, Adrien
    Beaussire-Trouvay, Ludivine
    Vernon, Virginie
    Dutherage, Marie
    Blondin, Valerie
    Elie, Caroline
    Bouhier-Leporrier, Karine
    Galais, Marie-Pierre
    Clabaut, Tifenn
    Bignon, Anne-Laure
    Parzy, Aurelie
    Gangloff, Alice
    Schwarz, Lilian
    Leveque, Emilie
    Sabourin, Jean-Christophe
    Michel, Pierre
    Vasseur, Nasrin
    Sefrioui, David
    Gilibert, Andre
    Di Fiore, Frederic
    BRITISH JOURNAL OF CANCER, 2025, : 814 - 821
  • [22] FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer
    Koca, Dogan
    Unal, Olcun Umit
    Oztop, Ilhan
    Yilmaz, Ugur
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2014, 25 (02): : 198 - 204
  • [23] Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
    Strickler, John H.
    Hurwitz, Herbert I.
    ONCOLOGIST, 2012, 17 (04): : 513 - 524
  • [24] The prognostic impact of NKA dynamics in first-line treatment of metastatic colorectal cancer
    Nederby, Line
    Raunkilde, Louise
    Jakobsen, Anders
    Jensen, Lars Henrik
    Havelund, Birgitte Mayland
    Wen, Sara Witting Christensen
    Hansen, Torben
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [26] Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer
    Ravaioli, A
    Marangolo, M
    Pasquini, E
    Rossi, A
    Amadori, D
    Cruciani, G
    Tassinari, D
    Oliverio, G
    Giovanis, P
    Turci, D
    Zumaglini, F
    Nicolini, M
    Panzini, I
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) : 2545 - 2550
  • [27] Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer
    Karacetin, D.
    Yalcin, B.
    Okten, B.
    Ozturk, S.
    Maral, O.
    Incekara, O.
    JOURNAL OF BUON, 2009, 14 (04): : 605 - 608
  • [28] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
  • [29] When to Use Triplet Chemotherapy as First-Line Treatment in Metastatic Colorectal Cancer
    Cremolini, Chiara
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 433 - 435
  • [30] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
12345